

COVID-19 Diagnostics (PCR Testing, Antibody Testing) and Therapy (Immunotherapy, Vaccines, Antiviral, Cell-based, Plasma therapy) Market Opportunity Assessment and Global Forecast to 2025

<https://marketpublishers.com/r/C17E5D691DD7EN.html>

Date: July 2020

Pages: 100

Price: US\$ 3,675.00 (Single User License)

ID: C17E5D691DD7EN

Abstracts

COVID-19 Diagnostics (PCR Testing, Antibody Testing) and Therapy (Immunotherapy, Vaccines, Antiviral, Cell-based, Plasma therapy) Market Opportunity Assessment and Global Forecast to 2025

The healthcare systems have been struggling to manage the COVID-19 patient population globally and hence the medical researchers are racing to find a solution to the pandemic. According to this latest publication from Meticulous Research®, the leading areas of research include antibodies, protein-based vaccines, antiviral, drug repurposes, RNA-based vaccines, non-replicating viral vectors, and cell-based therapies. While more than 50% of the therapies being developed are in preclinical stage, government initiatives, such as Emergency Use Authorization (EUA) by FDA, is expected to accelerate the research and development (R&D) process.

Based on healthcare options, the COVID-19 impact assessment is analyzed into diagnostics and treatments areas. The market opportunity of these products is estimated to reach USD 13.9 billion in 2025. The diagnostics segment is further divided into PCR-based testing and antibody testing. The treatment area is segmented into vaccines, immunotherapies, anti-virals, cell-based therapies, and other therapies. Vaccines and anti-virals are the most explored treatment options currently being investigated by researchers worldwide.

Geographically, North America has been the most affected region, primarily attributed to the U.S. being the most affected country having most number of confirmed cases as

well as deaths, globally. Other most affected nations include the U.K., Spain, France, Italy, Brazil, Germany, and India among others. Further, almost all the affected nations have experienced rapid economic decline leading GDP decline, increase in unemployment rates, and increase in the inflation rates. To overcome the situation, governments have imposed restriction on people movement as well as invested resources towards dealing with crisis and supporting all research and medical efforts towards developing a treatment option. The U.S., Canada, the U.K., Germany, China, and India are some of the key nations leading the research and production efforts geared towards developing COVID-19 medication.

Some of the key players engaged in COVID-19 diagnostics and treatment development include Roche Holding AG (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), AbbVie Corporation (U.S.), Gilead Sciences, Inc. (U.S.), Eli Lilly and Company (U.S.), Moderna, Inc. (U.S.), Novavax, Inc. (U.S.), Medicago, Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline (U.K.), Sanofi S.A. (France), Johnson & Johnson (U.S.), Sorrento Therapeutics, Inc. (U.S.), AstraZeneca Plc (U.K.), Pfizer, Inc. (U.S.), CTI Biopharma Corporation (U.S.), Oncolmmune, Inc. (U.S.), Athersys, Inc. (U.S.), Celularity, Inc. (U.S.), Pluristem Therapeutics (Israel), and Takeda Pharmaceuticals Company Ltd (Japan), among others.

Scope of the Report:

COVID-19 Product Pipeline

Diagnosis

PCR Testing

Antibody Testing

Treatment

Vaccines

Immunotherapy

Antiviral

Cell-based Therapy

Other Therapies

COVID-19: Impact on Healthcare Industry

Diagnostics

Rapid Test Kits

PCR/Rapid Antigen Testing/Nucleic Acid-Based Tests

Advantages Offered by PCR Testing in COVID -19 Diagnosis

Restraints

Key Companies

Antibody Testing/Serological Testing

Advantages Over Molecular Tests

Use of Antibody Testing for Herd Immunity Analysis and Easing
Lock-Down

Restraints

Key Companies

Therapies

Vaccines

Immunotherapies (Antibodies)

Monoclonal Antibody

T-Cell Therapy

Potential Game Changers: Antibodies

Ilaris (Canakinumab)

Sylvant (Siltuximab)

Lenzilumab

Ultomiris (Ravulizumab-Cwvz)

Tocilizumab

Anti-Virals

Potential Game Changers

Chloroquine and Hydroxychloroquine (HCQ)

Remdesivir

Cell-Based Therapies

Other Therapies

Plasma Therapy

Devices

COVID-19 Industry Impact Assessment, by Geography

North America

Europe

Asia-Pacific (APAC)

Rest of the World (RoW)

Contents

1. INTRODUCTION

- 1.1. Market Definition
- 1.2. Markets Covered
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Key Stakeholders

2. RESEARCH METHODOLOGY

- 2.1. Research Methodology Steps
- 2.2. Secondary and Primary Research Methodology
 - 2.2.1. Secondary Research
 - 2.2.1.1. Key Data from Secondary Sources
 - 2.2.2. Primary Research
 - 2.2.2.1. Key Data from Primary Sources
 - 2.2.2.2. Key Insights from Primary Sources
- 2.3. Market Size Estimation Methodology
- 2.4. Market Forecast Methodology
- 2.5. Market Breakdown and Data Triangulation

3. CORONAVIRUS: EPIDEMIOLOGY

- 3.1. About Coronavirus
- 3.2. Transmission & Symptoms
- 3.3. Prevention
- 3.4. Epidemiology

4. EXECUTIVE SUMMARY

- 4.1. Introduction
- 4.2. Global Economic Impact
- 4.3. COVID-19 Response
- 4.4. COVID-19 Research Pipeline
- 4.5. COVID-19 Pipeline Development Challenges
- 4.6. Key Companies

5. COVID-19: IMPACT ON HEALTHCARE INDUSTRY

5.1. Introduction

5.2. Key Trends & Impact on Healthcare Subsegments

5.3. Diagnostics

5.3.1. PCR / Rapid Antigen Testing / Nucleic Acid-Based Tests

5.3.1.1. Advantages Offered by PCR Testing in COVID -19 Diagnosis

5.3.1.2. Restraints

5.3.1.3. Key Companies

5.3.2. Antibody Testing / Serological Testing

5.3.2.1. Advantages Over Molecular Tests

5.3.2.2. Use of Antibody Testing for Herd Immunity Analysis and Easing Lock-Down

5.3.2.3. Restraints

5.3.2.4. Key Companies

5.4. Therapies

5.4.1. Vaccines

5.4.2. Immunotherapies (Antibodies)

5.4.2.1. Monoclonal Antibody

5.4.2.2. T-Cell Therapy

5.4.2.3. Potential Game Changers: Antibodies

5.4.2.3.1. Ilaris (Canakinumab)

5.4.2.3.2. Sylvan (Siltuximab)

5.4.2.3.3. Lenzilumab

5.4.2.3.4. Ultomiris (Ravulizumab-CWVZ)

5.4.2.3.5. Tocilizumab

5.4.3. Antivirals

5.4.3.1. Potential Game Changers

5.4.3.1.1. Chloroquine and Hydroxychloroquine (HCQ)

5.4.3.1.2. Remdesivir

5.4.4. Cell-Based Therapies

5.4.5. Other Therapies

5.4.5.1. Plasma Therapy

5.4.5.2. Devices

6. GEOGRAPHY IMPACT ASSESSMENT

6.1. Introduction

6.1.1. Global Virtual Fund-Raising Event to Raise USD 8 Billion for Coronavirus Vaccine

6.2. North America

6.2.1. COVID-19 Impact on the U.S. Economy

6.2.2. Significant R&D Investment by the U.S. Government for COVID-19 Treatment

6.2.3. High Dependence on the U.S. on Drugs Import Expected to Create Drug Shortages

6.2.4. Investments by Coalition for Epidemic Preparedness Innovations (CEPI) and Canadian Government

6.2.5. Canada Announced Investment of USD 192 Million on Vaccine Development as Well as Partnering with Industry and Academics

6.2.6. Creation of SARS-COV2 Vaccine-Bank by Researchers in Canada

6.3. Europe

6.3.1. Economic Impact of COVID-19: European Nations

6.3.2. European Firms to Lead the COVID-19 Treatment Researches

6.3.3. U.K. at Forefront in Drug Development Researches to Fight Covid-19

6.3.4. Partnership of European Pharmaceutical Giants – Sanofi and GSK To Develop COVID-19 Vaccine

6.3.5. German Vaccine Became the First European mRNA Vaccine to Enter Human Testing

6.3.6. Growing Interest of Billionaire in German Drug Development for COVID-19

6.4. APAC

6.4.1. Economic Impact of COVID-19: APAC

6.4.2. Asian Countries Leading the Diagnostics Test Commercialization

6.4.3. India In Favourable Position for Future Production Of COVID-19 Vaccine

6.4.4. Chinese Lockdown to Negatively Impact the Drugs Supply Chain

6.5. Rest of the World

6.5.1. Government Initiatives to Support COVID-19 Medicine Research & Other Drug Supply in Brazil

6.5.2. Saudi Arabia to Invest USD 2 Billion in Coronavirus Vaccine Development

6.5.3. Government Initiatives to Support Rapid Development of COVID-19 Therapy in South Africa

7. COMPETITIVE LANDSCAPE

7.1. Introduction

7.2. Agreements/Deals/Partnerships/Collaborations/Joint Ventures

7.3. R&D Updates

7.4. Authorization / Approvals

7.5. Donations Made

7.6. Funding Received

7.7. Capacity Expansion

7.8. Other Growth Strategies

8. COMPANY UPDATES

8.1. Company Segmentation

8.2. Diagnostic Companies

8.2.1. Roche Holding Ag

8.2.1.1. About the Firm

8.2.1.2. COVID-19 Pipeline

8.2.1.3. Recent Developments

8.2.2. Thermo Fisher Scientific, Inc.

8.2.2.1. About the Firm

8.2.2.2. COVID-19 Pipeline

8.2.2.3. Recent Developments

8.2.3. Becton, Dickinson and Company

8.2.3.1. About the Firm⁸⁶

8.2.3.2. COVID-19 Pipeline

8.2.3.3. Recent Developments

8.2.4. Abbott Laboratories

8.2.4.1. About the Firm

8.2.4.2. COVID-19 Pipeline

8.2.4.3. Recent Developments

8.2.5. Cepheid (Subsidiary of Danaher Corporation)

8.2.5.1. About the Firm

8.2.5.2. COVID-19 Pipeline

8.2.5.3. Recent Developments

8.3. Antivirals

8.3.1. Abbvie Corporation

8.3.1.1. About the Firm

8.3.1.2. COVID-19 Pipeline

8.3.1.3. Recent Developments

8.3.2. Gilead Sciences, Inc.

8.3.2.1. About the Firm

8.3.2.2. Covid-19- Pipeline

8.3.2.3. Recent Developments

8.3.3. Eli Lilly And Company

8.3.3.1. About the Firm

8.3.3.2. Covid-19- Products

- 8.3.3.3. Recent Developments
- 8.4. Vaccine Developers
 - 8.4.1. Moderna, Inc.
 - 8.4.1.1. About the Firm
 - 8.4.1.2. COVID-19 Pipeline
 - 8.4.1.3. Recent Developments
 - 8.4.2. Novavax, Inc.
 - 8.4.2.1. About the Firm
 - 8.4.2.2. COVID-19 Pipeline
 - 8.4.2.3. Recent Developments
 - 8.4.3. Medicago, Inc.
 - 8.4.3.1. About the Firm
 - 8.4.3.2. COVID-19 Pipeline
 - 8.4.3.3. Recent Developments
 - 8.4.4. Inovio Pharmaceuticals, Inc.
 - 8.4.4.1. About the Firm
 - 8.4.4.2. COVID-19 Pipeline
 - 8.4.4.3. Recent Developments
 - 8.4.5. GlaxoSmithKline (GSK)
 - 8.4.5.1. About the Firm
 - 8.4.5.2. COVID-19 Pipeline
 - 8.4.5.3. Recent Developments
 - 8.4.6. Sanofi S.A.
 - 8.4.6.1. About the Firm
 - 8.4.6.2. COVID-19 Pipeline
 - 8.4.6.3. Recent Developments
 - 8.4.7. Johnson & Johnson
 - 8.4.7.1. About the Firm
 - 8.4.7.2. COVID-19 Pipeline
 - 8.4.7.3. Recent Developments
- 8.5. Immunotherapy Firms
 - 8.5.1. Sorrento Therapeutics, Inc.
 - 8.5.1.1. About the Firm
 - 8.5.1.2. COVID-19 Pipeline
 - 8.5.1.3. Recent Developments
 - 8.5.2. Astrazeneca Plc
 - 8.5.2.1. About the Firm
 - 8.5.2.2. COVID-19 Pipeline
 - 8.5.2.3. Recent Developments

- 8.5.3. Pfizer, Inc.
 - 8.5.3.1. About the Firm
 - 8.5.3.2. COVID-19 Pipeline
 - 8.5.3.3. Recent Developments
- 8.5.4. Cti Biopharma Corporation
 - 8.5.4.1. About the Firm
 - 8.5.4.2. COVID-19 Pipeline
 - 8.5.4.3. Recent Developments
- 8.5.5. Oncoimmune, Inc.
 - 8.5.5.1. About the Firm
 - 8.5.5.2. COVID-19 Pipeline
 - 8.5.5.3. Recent Developments
- 8.6. Cell-Based Therapy
 - 8.6.1. Athersys, Inc.
 - 8.6.1.1. About the Firm
 - 8.6.1.2. COVID-19 Pipeline
 - 8.6.1.3. Recent Developments
 - 8.6.2. Cellularity, Inc.
 - 8.6.2.1. About the Firm
 - 8.6.2.2. COVID-19 Pipeline
 - 8.6.2.3. Recent Developments
 - 8.6.3. Pluristem Therapeutics, Inc.
 - 8.6.3.1. About the Firm
 - 8.6.3.2. COVID-19 Pipeline
 - 8.6.3.3. Recent Developments
- 8.7. Plasma Therapy
 - 8.7.1. Takeda Pharmaceutical Company Ltd
 - 8.7.1.1. About the Firm
 - 8.7.1.2. COVID-19 Pipeline
 - 8.7.1.3. Recent Developments

List Of Tables

LIST OF TABLES

Table 1 Health & Life Sciences Market Opportunity Assessment Post COVID-19, by Product Type, 2019–2025 (\$Million)

Table 2 Industry Trend & Impact Analysis on Healthcare Sub-Sectors Post COVID-19

Table 3 Diagnostics Market Opportunity for COVID-19, by Product Type, 2019–2025 (\$Million)

Table 4 Diagnostics Market Opportunity for COVID-19, by Geography, 2019–2025 (\$Million)

Table 5 PCR Cycle and Corresponding No. of Target Copies Produced

Table 6 PCR Testing Market Opportunity for COVID-19, by Geography, 2019–2025 (\$Million)

Table 7 Antibody Testing Market Opportunity Assessment for COVID-19, by Geography, 2019–2025 (\$Million)

Table 8 Therapy Market Opportunity Assessment for COVID-19, by Product Type, 2019–2025 (\$Million)

Table 9 Therapy Market Opportunity Assessment for COVID-19, by Geography, 2021–2025 (\$Million)

Table 10 Key Vaccine Pipeline For COVID-19 (Non-Exhaustive, As of May 05, 2020)

Table 11 Vaccines Market Opportunity for COVID-19, by Geography, 2021–2025 (\$Million)

Table 12 Immunotherapy Pipeline For COVID-19 (Non-Exhaustive, As of May 05, 2020)

Table 13 Immunotherapy Market Opportunity for COVID-19, by Geography, 2021–2025 (\$Million)

Table 14 Antiviral Pipeline For COVID-19 (Non-Exhaustive, As of May 05, 2020)

Table 15 Antiviral Market Opportunity for Covid-19, by Geography, 2021–2025 (\$Million)

Table 16 Cell-Based Therapy Pipeline for COVID-19 (Non-Exhaustive, As of May 05, 2020)

Table 17 Cell Based Therapy Market Opportunity for COVID-19, by Geography, 2021–2025 (\$Million)

Table 18 Plasma Therapies in Pipeline for COVID-19

Table 19 COVID-19 Devices Platforms in Pipeline

Table 20 Other Therapies Market Opportunity for COVID-19, by Geography, 2021–2025 (\$Million)

Table 21 Life Sciences Products Market for COVID-19, by Geography, 2019–2025 (\$Million)

Table 22 COVID-19 Treatment Investments, by BARDA (U.S.)

Table 23 North America: COVID-19 Health & Life Sciences Market Opportunity, 2019–2025 (\$Million)

Table 24 North America: Diagnostics Market Opportunity for COVID-19, 2019–2025 (\$Million)

Table 25 North America: Therapy Market Opportunity for COVID-19, by Product Type, 2021–2025 (\$Million)

Table 26 Key Economic Indicators: Europe (2019 – 2021)

Table 27 Europe: Health & Life Sciences Market Opportunity for COVID-19, 2019–2025 (\$Million)

Table 28 Europe: COVID-19 Diagnostics Market Opportunity, 2019–2025 (\$Million)

Table 29 Europe: Therapy Market Opportunity for COVID-19, by Product Type, 2021–2025 (\$Million)

Table 30 Key Economic Indicators: Asia (2019 – 2021)

Table 31 APAC: Health & Life Sciences Market Opportunity for COVID-19, 2019–2025 (\$Million)

Table 32 APAC: Diagnostics Market Opportunity for COVID-19, 2019–2025 (\$Million)

Table 33 APAC: Therapy Market Opportunity for COVID-19, by Product Type, 2021–2025 (\$Million)

Table 34 RoW: Health & Life Sciences Market Opportunity for COVID-19, 2019–2025 (\$Million)

Table 35 RoW: Diagnostics Market Opportunity for COVID-19, 2019–2025 (\$Million)

Table 36 RoW: Therapy Market Opportunity for COVID-19, by Product Type, 2021–2025 (\$Million)

List Of Figures

LIST OF FIGURES

Figure 1 Research Methodology

Figure 2 Market Size Estimation Methodology: Bottom-Up Approach

Figure 3 Market Size Estimation Methodology: Top-Down Approach

Figure 4 Research Design

Figure 5 Data Triangulation Methodology

Figure 6 Global Coronavirus Cases, As of 15 May 2020

Figure 7 GDP Trend Across the U.S., U.K., Germany, China, and India (2019, 2020 (F), and 2021 (F))

Figure 8 COVID-19 Treatment Pipeline, by Development Stage (As of May 2020)

Figure 9 Life Sciences Market Segmentation Impacted by Covid-19

Figure 10 COVID-19 Treatment Pipeline in Development, by type and Development Stage

Figure 11 Vaccine Pipeline, by Category & Development Stage

Figure 12 Immunotherapy / Antibodies Pipeline, by Development Stage (As of May 2020)

Figure 13 Antiviral Pipeline, by Development Stage (As of May 2020)

Figure 14 Cell-Based Therapy Pipeline, by Development Stage (As of May 2020)

Figure 15 Key Economic Indicators: U.S. (2018 To April 2020 & Forecast to 2021)

Figure 16 Key Growth Strategies, by Development & by Company, Feb – May 2020

Figure 17 Key Firms Active in COVID-19 Product Development

I would like to order

Product name: COVID-19 Diagnostics (PCR Testing, Antibody Testing) and Therapy (Immunotherapy, Vaccines, Antiviral, Cell-based, Plasma therapy) Market Opportunity Assessment and Global Forecast to 2025

Product link: <https://marketpublishers.com/r/C17E5D691DD7EN.html>

Price: US\$ 3,675.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C17E5D691DD7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970